Stifel Financial
CRNX

Stifel Financial’s Crinetics Pharmaceuticals CRNX Stock Holding History

Stifel Financial’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$793K Buy
21,200
+142
+0.7% +$5.28K ﹤0.01% 2699
2026
Q1 		$765K Sell
21,058
-142
-0.7% -$6.34K ﹤0.01% 2609
2025
Q4 		$987K Sell
21,200
-533
-2% -$23.7K ﹤0.01% 2443
2025
Q3 		$905K Buy
21,733
+277
+1% +$8.86K ﹤0.01% 2453
2025
Q2 		$617K Buy
21,456
+12,458
+138% +$385K ﹤0.01% 2646
2025
Q1 		$302K Sell
8,998
-896
-9% -$33.5K ﹤0.01% 2967
2024
Q4 		$506K Sell
9,894
-144
-1% -$8.06K ﹤0.01% 2666
2024
Q3 		$513K Sell
10,038
-520
-5% -$26.8K ﹤0.01% 2665
2024
Q2 		$473K Buy
10,558
+346
+3% +$16K ﹤0.01% 2658
2024
Q1 		$478K Buy
+10,212
New +$400K ﹤0.01% 2640

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stifel Financial's CRNX Position: Q2 2026 in Review

Stifel Financial increased its Crinetics Pharmaceuticals (CRNX) stake by 0.67% in Q2 2026, buying an estimated $5.28K and bringing the position to 21,200 shares worth $793K. The position accounts for ﹤0.01% of the portfolio, ranked #2699.

Stifel Financial first reported a position in CRNX in Q1 2024 and has held it in 10 quarters since. The position peaked at $987K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Stifel Financial held 21,200 shares of Crinetics Pharmaceuticals worth $793K as of Q2 2026.
  • Stifel Financial bought 142 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $5.28K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #2699 holding.
  • Stifel Financial first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Stifel Financial's Crinetics Pharmaceuticals position peaked at $987K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.